Therefore, our study aims to analyze the value of serum NRG1 levels in prostate cancer patients before ADT, as well as NRG1 levels in biopsy tissues and NRG1 gene expression, for predicting CRPC progression within one year of ADT. The gene discussed is NRG1; the disease is Familial prostate cancer.